Related references
Note: Only part of the references are listed.Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation
Juan Liu et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2021)
UCSF ChimeraX: Structure visualization for researchers, educators, and developers
Eric F. Pettersen et al.
PROTEIN SCIENCE (2021)
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2021)
Third-line therapy for chronic myeloid leukemia: current status and future directions
Jorge Cortes et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Can machine learning consistently improve the scoring power of classical scoring functions? Insights into the role of machine learning in scoring functions
Chao Shen et al.
BRIEFINGS IN BIOINFORMATICS (2021)
Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds
Ewgenij Proschak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Properties of FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
The implementation of RAAF in the OECD QSAR Toolbox
Chanita Kuseva et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2019)
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Fiona H. Tan et al.
ONCOTARGETS AND THERAPY (2019)
Kinase-targeted cancer therapies: progress, challenges and future directions
Khushwant S. Bhullar et al.
MOLECULAR CANCER (2018)
Kinase inhibitors: the road ahead
Fleur M. Ferguson et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
T315L: a novel mutation within BCR-ABL kinase domain confers resistance against ponatinib
Dongmei Wang et al.
LEUKEMIA & LYMPHOMA (2017)
Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors
Ami B. Patel et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
Antoine Daina et al.
SCIENTIFIC REPORTS (2017)
A Decade of Nilotinib and Dasatinib: From In Vitro Studies to First-Line Tyrosine Kinase Inhibitors
Thomas O'Hare
CANCER RESEARCH (2016)
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
Jeffrey H. Lipton et al.
LANCET ONCOLOGY (2016)
Aminopyrimidine derivatives as protein kinases inhibitors. Molecular design, synthesis, and biologic activity
E. V. Koroleva et al.
RUSSIAN JOURNAL OF ORGANIC CHEMISTRY (2016)
Fast, accurate, and reliable molecular docking with QuickVina 2
Amr Alhossary et al.
BIOINFORMATICS (2015)
The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities
Samuel Genheden et al.
EXPERT OPINION ON DRUG DISCOVERY (2015)
A Comprehensive Comparison of the IEFPCM and SS(V)PE Continuum Solvation Methods with the COSMO Approach
A. Klamt et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2015)
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
Tim H. Bruemmendorf et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
Hagop M. Kantarjian et al.
BLOOD (2014)
Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set
Huiyong Sun et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2014)
Shifting from the single to the multitarget paradigm in drug discovery
Jose L. Medina-Franco et al.
DRUG DISCOVERY TODAY (2013)
Unitary Optimization of Localized Molecular Orbitals
Susi Lehtola et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2013)
Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parameters
James J. P. Stewart
JOURNAL OF MOLECULAR MODELING (2013)
Assessing the Performance of MM/PBSA and MM/GBSA Methods. 3. The Impact of Force Fields and Ligand Charge Models
Lei Xu et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2013)
Trust Region Minimization of Orbital Localization Functions
Ida-Marie Hoyvik et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2012)
Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Rational Approaches to Improving Selectivity in Drug Design
David J. Huggins et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
Tianjun Zhou et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2011)
NNScore 2.0: A Neural-Network Receptor-Ligand Scoring Function
Jacob D. Durrant et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
BINANA: A novel algorithm for ligand-binding characterization
Jacob D. Durrant et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2011)
Computer Review of ChemDraw Ultra 12.0
Kimberley R. Cousins
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2011)
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Hagop M. Kantarjian et al.
LANCET ONCOLOGY (2011)
Raf kinases in cancer-roles and therapeutic opportunities
G. Maurer et al.
ONCOGENE (2011)
Software News and Update AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading
Oleg Trott et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
Stephen Blake et al.
CLINICAL IMMUNOLOGY (2008)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Protein kinase inhibitors: Insights into drug design from structure
MEM Noble et al.
SCIENCE (2004)
Development and testing of a general amber force field
JM Wang et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
Mutational analysis of the tyrosine kinome in colorectal cancers
A Bardelli et al.
SCIENCE (2003)
Share Paper
